News and Trends 17 Mar 2023Beyond Biotech podcast 38: Hello Tomorrow Global Summit The Hello Tomorrow Global Summit took place in Paris last week (March 8-10), and we feature interviews with four of… March 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Mar 2023Can CRISPR bring back extinct animals? The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology -… March 10, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023Moderna and Life Edit Therapeutics look to speed up gene editing therapies Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio… February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023AI boosts genome editing Researchers at the University of Zurich have developed a new tool that uses artificial intelligence to predict the efficacy of… February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023Milestone for gene-edited therapy for sickle cell disease Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application… January 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022PACT Pharma reports data from CRISPR cancer study PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene… November 11, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022What’s on the horizon for gene editing-based therapies? Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such… November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could… October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 17 Oct 2022CRISPR gene editing: a key tool for counteracting climate change Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing technology could fight climate change… October 17, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022The challenges of translating CRISPR to the clinic CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of disease processes, and for the… October 17, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki… September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies.… September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022Lesaffre acquires genome editing company Recombia Biosciences Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on… September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered.… August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by ProteoGenix 16 Aug 2022Optimizing bioproduction using transient expression systems During drug development, biologics often fail to transition from the preclinical to the clinical stage, resulting in huge losses in… August 16, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
Interview 10 Aug 2022How the UK precision breeding bill could unshackle gene editing The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene… August 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022Epigenic Therapeutics raises $20M for gene editing technology Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. … August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T… August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2022How DNA sequencing can safeguard against biodiversity loss Preserving Earth’s biodiversity is crucial as we rely on healthy ecosystems for many services, from clean air and water to… July 26, 2022 - 8 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022Replay launches with $55M to reprogram biology by writing and delivering big DNA Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed… July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email